We are a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Our lead product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Having successfully completed multiple preclinical studies and seven clinical trials with AQX-1125, we are now advancing towards pivotal Phase 3 trials with AQX-1125 in our lead indication of bladder pain syndrome/interstitial cystitis (BPS/IC). Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.